Kodiak Sciences Inc. (NASDAQ: KOD) is a Healthcare company (Biotechnology) with a market capitalization of $6.3B. The Maz Rating grades it against the other companies in its sector.
Kodiak Sciences Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $96.80, Kodiak Sciences Inc. trades at 483.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -287.6%, return on invested capital of -157.0% and a free cash flow yield of -2.7%. On the balance sheet: a debt-to-equity ratio of 11.66 and a current ratio of 1.70. Over the past 52 weeks the share price ranged from $18.15 to $112.79, with a beta of 2.02.
Kodiak Sciences Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 14 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Kodiak Sciences Inc. (KOD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.30% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.13% / 30% · Interest income / Revenue 89900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.30% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.04% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 89900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.30% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.04% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 89900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 33.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 52.9% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 89900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 47.8% / 33.33% · (Cash+ST Inv) / Total Assets 42.3% / 33.33% · (Cash+Recv) / Total Assets 42.3% / 33.33% · Interest income / Revenue 89900000.0% / 5% | Fail |
No. As of September 2026, Kodiak Sciences Inc. (KOD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Kodiak Sciences Inc. is over the AAOIFI limit on Interest income / Revenue.
About 89900000.0% of each dividend: Kodiak Sciences Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.